CN100361658C - 更昔洛韦原位眼凝胶组合物及其制备方法 - Google Patents
更昔洛韦原位眼凝胶组合物及其制备方法 Download PDFInfo
- Publication number
- CN100361658C CN100361658C CNB2005100466731A CN200510046673A CN100361658C CN 100361658 C CN100361658 C CN 100361658C CN B2005100466731 A CNB2005100466731 A CN B2005100466731A CN 200510046673 A CN200510046673 A CN 200510046673A CN 100361658 C CN100361658 C CN 100361658C
- Authority
- CN
- China
- Prior art keywords
- gel
- value
- ganciclovir
- eye
- original position
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960002963 ganciclovir Drugs 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 60
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 20
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- 235000011121 sodium hydroxide Nutrition 0.000 claims abstract description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 15
- 229920002307 Dextran Polymers 0.000 claims abstract description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004359 castor oil Substances 0.000 claims abstract description 13
- 235000019438 castor oil Nutrition 0.000 claims abstract description 13
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 13
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 13
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 11
- 229960001631 carbomer Drugs 0.000 claims abstract description 11
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- 206010038910 Retinitis Diseases 0.000 claims abstract description 5
- 206010023332 keratitis Diseases 0.000 claims abstract description 5
- 230000003612 virological effect Effects 0.000 claims abstract description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 14
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 12
- -1 card pool nurse Chemical compound 0.000 claims description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 230000008859 change Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 13
- 235000011187 glycerol Nutrition 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 11
- 230000007704 transition Effects 0.000 abstract description 10
- 210000004087 cornea Anatomy 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 229960002086 dextran Drugs 0.000 abstract 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 229960002668 sodium chloride Drugs 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 43
- 239000000243 solution Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 15
- 239000003889 eye drop Substances 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 229960000502 poloxamer Drugs 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 206010023683 lagophthalmos Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000004083 nasolacrimal duct Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229920001617 Vinyon Polymers 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
pH值 | 粘稠度(cPa) | pH值 | 粘稠度(cPa) | pH值 | 粘稠度(cPa) |
4.65 | 12.8 | 5.30 | 62.4 | 5.71 | 179.9 |
4.90 | 19.2 | 5.37 | 80.5 | 5.82 | 243.9 |
5.03 | 26.3 | 5.49 | 102.7 | 7.20 | 363.8 |
5.15 | 37.8 | 5.62 | 144.1 | 8.22 | 311.3 |
0.1M NaOH(ml) | 0 | 30 | 40 | 50 | 60 | 65 | 70 | 75 | 80 | 100 |
pH值 | 3.89 | 4.27 | 4.42 | 4.58 | 4.77 | 4.87 | 4.98 | 5.16 | 5.28 | 6.04 |
cPa(34<sup>*</sup>,60rpm) | 4.81 | 6.64 | 8.73 | 11.19 | 14.95 | 18.23 | 22.86 | 37.58 | 65.46 | 172.54 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100466731A CN100361658C (zh) | 2005-06-15 | 2005-06-15 | 更昔洛韦原位眼凝胶组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100466731A CN100361658C (zh) | 2005-06-15 | 2005-06-15 | 更昔洛韦原位眼凝胶组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1879625A CN1879625A (zh) | 2006-12-20 |
CN100361658C true CN100361658C (zh) | 2008-01-16 |
Family
ID=37518129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100466731A Active CN100361658C (zh) | 2005-06-15 | 2005-06-15 | 更昔洛韦原位眼凝胶组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100361658C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102210686A (zh) * | 2011-04-07 | 2011-10-12 | 罗诚 | 一种含更昔洛韦化合物的药物组合物及其制备方法 |
CN102764231B (zh) * | 2012-08-10 | 2014-06-11 | 何群 | 治疗单纯疱疹病毒性角膜炎的眼用凝胶剂及其制备方法 |
CN108938557B (zh) * | 2017-05-25 | 2021-08-10 | 中山大学 | pH敏感型熊胆眼用即型凝胶 |
CN117338787A (zh) * | 2023-11-24 | 2024-01-05 | 南京恒道医药科技股份有限公司 | 一种眼用药物组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1456157A (zh) * | 2002-05-10 | 2003-11-19 | 刘继东 | 左旋氧氟沙星眼用凝胶 |
CN1554345A (zh) * | 2003-12-29 | 2004-12-15 | 湖北丽益医药科技有限公司 | 阿昔洛韦眼用凝胶制剂及制备方法 |
CN1626090A (zh) * | 2003-08-25 | 2005-06-15 | 成都三明药物研究所 | 一种用于眼部的抗病毒药物组合物及其制备方法 |
-
2005
- 2005-06-15 CN CNB2005100466731A patent/CN100361658C/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1456157A (zh) * | 2002-05-10 | 2003-11-19 | 刘继东 | 左旋氧氟沙星眼用凝胶 |
CN1626090A (zh) * | 2003-08-25 | 2005-06-15 | 成都三明药物研究所 | 一种用于眼部的抗病毒药物组合物及其制备方法 |
CN1554345A (zh) * | 2003-12-29 | 2004-12-15 | 湖北丽益医药科技有限公司 | 阿昔洛韦眼用凝胶制剂及制备方法 |
Non-Patent Citations (1)
Title |
---|
原位胶化缓释滴眼剂的研究进展. 钟延强,蒋华芳等.药学服务与研究,第3卷第3期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1879625A (zh) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2153234C (en) | Aqueous drug composition having property of reversible thermosetting gelation | |
Lou et al. | Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles | |
CN102078284B (zh) | 一种含加替沙星的眼用凝胶剂及其制备方法 | |
Huang et al. | Preparation, pharmacokinetics and pharmacodynamics of ophthalmic thermosensitive in situ hydrogel of betaxolol hydrochloride | |
JP2001521885A (ja) | 水溶性薬剤を含有する持効性眼科用組成物 | |
CN101185650B (zh) | 喷昔洛韦眼用温度敏感原位凝胶制剂及其制备方法 | |
CN102283799B (zh) | 一种阿奇霉素凝胶型滴眼液及其制备工艺 | |
IE912033A1 (en) | Reversible gelation compositions and methods of use | |
CN107854424A (zh) | 一种阿奇霉素眼用原位凝胶及其制备方法 | |
CN109260146A (zh) | 地夸磷索钠眼用即用型凝胶滴眼液及制备方法 | |
CN104055729A (zh) | 阿奇霉素滴眼液及其制备方法 | |
CN101002788A (zh) | 一种含黄芪甲苷活性成分鼻用凝胶剂 | |
CN100361658C (zh) | 更昔洛韦原位眼凝胶组合物及其制备方法 | |
WO2011018800A2 (en) | A novel in-situ gel forming solution for ocular drug delivery | |
CN105106107B (zh) | 一种苄达赖氨酸眼用结冷胶原位凝胶剂及其制备方法 | |
EP1189595B1 (en) | Ophthalmic compositions in form of aqueous gels | |
CN101491525A (zh) | 四氢嘧啶在制备治疗干眼症药物中的应用 | |
CN101185645B (zh) | 色甘酸钠凝胶滴眼液及制备工艺 | |
CN1302812C (zh) | 含海藻糖和玻璃酸的眼部用药传递系统及其制备方法 | |
Lei et al. | Sustained ocular delivery of desmopressin acetate via thermoreversible in situ gel formulation: Preparation and in vitro/in vivo evaluation | |
CN100548273C (zh) | 鱼腥草眼用即型凝胶制剂 | |
CN101543509B (zh) | 含有硫酸软骨素的眼用凝胶剂及其制备方法 | |
CN103977011A (zh) | 含有曲伏前列素和噻吗洛尔的眼用凝胶剂及其制备方法 | |
CN101278895A (zh) | 一种眼用即型凝胶制剂及其制备方法 | |
CN103735518A (zh) | 马来酸噻吗洛尔缓释微球的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. Assignor: Liu Jidong Contract fulfillment period: 2008.9.29 to 2013.9.29 Contract record no.: 2008210000056 Denomination of invention: In situ-forming eye gel composition of ganciclovir and preparation method thereof Granted publication date: 20080116 License type: Exclusive license Record date: 20081105 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.29 TO 2013.9.29; CHANGE OF CONTRACT Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD. Effective date: 20081105 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. Assignor: Liu Jidong Contract fulfillment period: 2008.9.29 to 2013.9.29 Contract record no.: 2008210000056 Denomination of invention: In situ-forming eye gel composition of ganciclovir and preparation method thereof Granted publication date: 20080116 License type: Exclusive license Record date: 20081105 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.29 TO 2013.9.29; CHANGE OF CONTRACT Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD. Effective date: 20081105 |
|
ASS | Succession or assignment of patent right |
Owner name: SHENYANG XINGQI MEDICINE CO., LTD. Free format text: FORMER OWNER: LIU JIDONG Effective date: 20111013 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111013 Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 Shenyang economic and Technological Development Zone, Liaoning, No. three, No. 12, No. 4, No. Patentee before: Liu Jidong |
|
C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENYANG XINGQI MEDICINE CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 110024, 4, 12, three street, Shenyang economic and Technological Development Zone Patentee after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: No. 25 Xinyunhe Road, Shenyang Area, China (Liaoning) Pilot Free Trade Zone, Shenyang City, Liaoning Province, 110000 Patentee after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: No. 12, 4, three street, Shenyang economic and Technological Development Zone Patentee before: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |